The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Learn how the right NGS technology can enhance clinical research while supporting downstream efforts toward global commercialization.